Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | RAPGEF3 | O95398 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25796919 | 0.82 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL84872 | 0.79 | MEN1 (0.48) | MEN1KMT2ACNR2CNR1EGFR | |
| SCHEMBL20320548 | 0.78 | CNR2 (0.38) | CNR2CNR1NPC1RAB9A | |
| SCHEMBL1012771 | 0.77 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL25803019 | 0.77 | MEN1 (0.38) | MEN1KMT2AEGFRRAPGEF3NPC1 | |
| SCHEMBL25799445 | 0.76 | CNR2 (0.39) | CNR2CNR1NPC1RAB9A | |
| SCHEMBL18471564 | 0.74 | MEN1 (0.44) | MEN1KMT2ACNR2CNR1EGFR | |
| SCHEMBL23966689 | 0.74 | MEN1 (0.44) | MEN1KMT2ACNR2CNR1EGFR | |
| SCHEMBL9891488 | 0.74 | MEN1 (0.44) | MEN1KMT2ACNR2CNR1EGFR | |
| SCHEMBL13230275 | 0.74 | MEN1 (0.44) | MEN1KMT2ACNR2CNR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | MEN1 1766/4885KMT2A 2554/4885CNR2 3084/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | MEN1 3098/4885KMT2A 4530/4885CNR2 4544/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | MEN1 1766/4885KMT2A 2554/4885CNR2 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.